Loading…
Loading…
Brookfield Real Assets Income Fund Inc. (NYSE: RA - Get Free Report) was the target of a large decrease in short interest in August. As of August 14th, there was short interest totaling 56,549 shares, a decrease of 36.8% from the July 30th total of 89,421 shares. Based on an average daily trading volume, of 144,278
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD). Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics, he has overseen.
Brookfield Real Assets Income Fund is a fixed income CEF, not a direct real assets holder, despite its name. RA primarily invests in corporate and securitized credit, with only 7.9% in equities and no direct commodity or real estate exposure. The fund's 10% distribution is supported by significant return of capital (~30%), with true cash flow yield closer to 7%.
Brookfield Real Assets Income Fund Inc. (NYSE: RA - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $12.93 and traded as high as $12.97. Brookfield Real Assets Income Fund shares last traded at $12.9540, with a volume of 122,956 shares
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund's monthly distributions for July, August and September 2026.
NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (the “Fund”) (NYSE: RA) today announced upcoming portfolio management changes at Oaktree Fund Advisors, LLC (“Oaktree”), the sub-adviser responsible for managing the Fund's securitized credit allocation.
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data acros